KPAX002-1: Parkinson's Disease
Phase 2 ready. K-PAX is ready to implement its phase 2 program to demonstrate the safety and efficacy of KPAX002 as a treatment for Parkinson's disease fatigue and excessive daytime sleepiness. These symptoms represent a key unmet need in the treatment of this condition.
KPAX002-2: Alzheimer's Disease
Phase 2 ready. We are ready to implement a proof-of-concept trial to demonstrate the safety and efficacy of KPAX002 as a treatment for the decreased alertness and impaired cognitive symptoms of Alzheimer's disease.
KPAX002-3: Myalgic Encephalomyelitis/CFS
Phase 3 ready. We have successfully completed phase 1 and phase 2 trials in patients with ME/CFS and are now ready to implement our pivotal phase 3 trial. The FDA has issued a draft guidance to industry and is on record as being highly motivated to approve a first treatment for this disease. KPAX002 is the leading candidate ready to take advantage of this unique opportunity. KPAX002 possesses strong IP protection through 2032.